Title: Recurrent Clostridium difficile Infection: Enter Fidaxomicin
Abstract:Recurrence of Clostridium difficile infection (CDI) is common, whether metronidazole or vancomycin is used as initial therapy. Fidaxomicin, a new macrocyclic antibiotic that has no cross-resistance wi...Recurrence of Clostridium difficile infection (CDI) is common, whether metronidazole or vancomycin is used as initial therapy. Fidaxomicin, a new macrocyclic antibiotic that has no cross-resistance with other antibiotics, is more active in vitro than vancomycin against clinical C. difficile isolates; in a phase II trial, it was associated with good clinical response and …Read More
Publication Year: 2011
Publication Date: 2011-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot